- Home
- PGY vs PRAX Comparison
PGY vs PRAX Comparison
Compare PGY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGY
- PRAX
- Stock Information
- Founded
- PGY 2016
- PRAX 2015
- Country
- PGY United States
- PRAX United States
- Employees
- PGY N/A
- PRAX N/A
- Industry
- PGY Finance: Consumer Services
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- PGY Finance
- PRAX Health Care
- Exchange
- PGY Nasdaq
- PRAX Nasdaq
- Market Cap
- PGY 2.6B
- PRAX 950.8M
- IPO Year
- PGY N/A
- PRAX 2020
- Fundamental
- Price
- PGY $41.95
- PRAX $40.45
- Analyst Decision
- PGY Strong Buy
- PRAX Strong Buy
- Analyst Count
- PGY 8
- PRAX 9
- Target Price
- PGY $37.13
- PRAX $94.44
- AVG Volume (30 Days)
- PGY 3.4M
- PRAX 406.2K
- Earning Date
- PGY 11-11-2025
- PRAX 11-05-2025
- Dividend Yield
- PGY N/A
- PRAX N/A
- EPS Growth
- PGY N/A
- PRAX N/A
- EPS
- PGY N/A
- PRAX N/A
- Revenue
- PGY $1,153,015,000.00
- PRAX $7,765,000.00
- Revenue This Year
- PGY $27.97
- PRAX N/A
- Revenue Next Year
- PGY $16.50
- PRAX $22.22
- P/E Ratio
- PGY N/A
- PRAX N/A
- Revenue Growth
- PGY 24.59
- PRAX 338.45
- 52 Week Low
- PGY $8.20
- PRAX $26.70
- 52 Week High
- PGY $42.20
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- PGY 72.60
- PRAX 38.61
- Support Level
- PGY $36.07
- PRAX $37.19
- Resistance Level
- PGY $39.09
- PRAX $40.69
- Average True Range (ATR)
- PGY 2.40
- PRAX 2.41
- MACD
- PGY 0.28
- PRAX -0.61
- Stochastic Oscillator
- PGY 97.28
- PRAX 27.77
About PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.